Literature DB >> 23442586

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac (®) ) in India.

Prasad S Kulkarni1, Sidram K Raut, Rajeev M Dhere.   

Abstract

A live attenuated pandemic H1N1 influenza vaccine was developed in India. A post marketing surveillance was conducted retrospectively in healthy individuals (³ 3 years) who were vaccinated intranasally around one year before. After consent, the subjects recorded adverse events developing within 42 days. Among 7565 individuals (3 - 85 years), a total of 81 solicited adverse reactions (1%) were reported in 49 subjects (0.65%). The reactions included mild to moderate respiratory symptoms. No H1N1 case was encountered during one year postvaccination. The data show the safety of the live attenuated influenza vaccine platform developed in India.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23442586      PMCID： PMC3667925          DOI： 10.4161/hv.22317

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  5 in total

1.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

Authors:  W E P Beyer; A M Palache; J C de Jong; A D M E Osterhaus
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

Review 2.  A pandemic influenza vaccine in India: from strain to sale within 12 months.

Authors:  Rajeev Dhere; Leena Yeolekar; Prasad Kulkarni; Ravi Menon; Vivek Vaidya; Milan Ganguly; Parikshit Tyagi; Prajakt Barde; Suresh Jadhav
Journal:  Vaccine       Date:  2011-07-01       Impact factor: 3.641

3.  Answering autobiographical questions: the impact of memory and inference on surveys.

Authors:  N M Bradburn; L J Rips; S K Shevell
Journal:  Science       Date:  1987-04-10       Impact factor: 47.728

4.  Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-05-08       Impact factor: 17.586

5.  Pandemic influenza (H1N1) 2009 is associated with severe disease in India.

Authors:  Akhilesh C Mishra; Mandeep S Chadha; Manohar L Choudhary; Varsha A Potdar
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240
  5 in total
  12 in total

Review 1.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

Review 2.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

Review 3.  Mucosal Vaccination: A Promising Alternative Against Flaviviruses.

Authors:  Rosendo Luria-Pérez; Luis A Sánchez-Vargas; Paola Muñoz-López; Gabriela Mellado-Sánchez
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

Review 4.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

5.  Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.

Authors:  Prashant V Nigwekar; Anuj Kumar; Vikram V Padbidri; Amlan Choudhury; Amol B Chaudhari; Prasad S Kulkarni
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.228

6.  Development of a stable liquid formulation of live attenuated influenza vaccine.

Authors:  Jessica A White; Marcus Estrada; E Alexander Flood; Kutub Mahmood; Rajeev Dhere; Dexiang Chen
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

7.  Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.

Authors:  Larisa Rudenko; Leena Yeolekar; Irina Kiseleva; Irina Isakova-Sivak
Journal:  Vaccine       Date:  2016-09-01       Impact factor: 3.641

8.  In silico analysis and molecular characterization of Influenza A (H1N1) pdm09 virus circulating and causing major outbreaks in central India, 2009-2019.

Authors:  Arshi Siddiqui; Rashmi Chowdhary; Harjeet Singh Maan; Sudhir Kumar Goel; Nidhi Tripathi; Anil Prakash
Journal:  Iran J Microbiol       Date:  2020-10

9.  Epidemiological and clinical profile of Influenza A(H1N1) pdm09 in Odisha, eastern India.

Authors:  B Dwibedi; J Sabat; S Dixit; S Rathore; S Subhadra; S Panda; S S Pati; M Mandal; L M Ho; B Thakur; S K Kar
Journal:  Heliyon       Date:  2019-10-15

Review 10.  The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation.

Authors:  Jieliang Wang; Ying Peng; Haiyue Xu; Zhengrong Cui; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2020-08-05       Impact factor: 3.246
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.